Lung cancer

BGB-LC-201

A Phase 2, Open-label, Multi-arm;Study of Tislelizumab in Combination With Investigational;Agents With or Without Chemotherapy in Patients With;Previously Untreated, Locally Advanced, Unresectable, or;Metastatic Non-Small Cell Lung Cancer.

Open at Paris since : 13/05/2024
Target : Adult
Phase : Phase II

Trial description

To assess the antitumor activity of;tislelizumab plus investigational agent(s);with or without chemotherapy.

Url of the trial

Main investigator

NICOLAS GIRARD

Professeur - Médecin

Contact